Kyushu Express announced that the company's holding subsidiary added 2 new varieties to the “National Essential Drug Catalogue”, including telmisartan tablets from Beijing Jingfeng Pharmaceutical Group Co., Ltd. and terbinafine hydrochloride cream from Beijing Jingfeng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Beijing Jingfeng Pharmaceutical Co., Ltd., which will take effect on September 1, 2026. The addition to the catalogue helps expand the product market, but drug sales are affected by multiple factors, and there is uncertainty.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.